Kohjin Bio Co., Ltd. Logo

Kohjin Bio Co., Ltd.

A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.

177A | T

Overview

Corporate Details

ISIN(s):
JP3283630006
LEI:
Country:
Japan
Address:
坂戸市千代田5−1−3
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development, manufacture, and sale of products for life sciences research and clinical applications. Its core offerings include tissue and cell culture media, media for microbial testing, and in-vitro diagnostic reagents. The company also provides animal-derived biological materials such as blood and serum. A key area of focus is regenerative medicine and cell therapy, where Kohjin Bio operates as a leading Contract Development and Manufacturing Organization (CDMO) in Japan, producing specialized culture media. Additionally, the company offers bioservices, including immunology contracts and the processing of cells for cancer immune therapies through partnerships with medical institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:30
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 07:30
Interim Report
半期報告書-第45期(2025/04/01-2026/03/31)
Japanese 215.4 KB
2025-06-27 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-06-24 09:09
Governance Information
内部統制報告書-第44期(2024/04/01-2025/03/31)
Japanese 25.0 KB
2025-06-24 09:08
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 09:06
Annual Report
有価証券報告書-第44期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2024-11-14 07:30
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-14 07:30
Interim Report
半期報告書-第44期(2024/04/01-2025/03/31)
Japanese 200.4 KB
2024-07-04 02:15
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2024-06-28 08:09
Registration Form
確認書
Japanese 9.0 KB
2024-06-28 08:00
Annual Report
有価証券報告書-第43期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-04-25 05:44
Major Shareholding Notification
臨時報告書
Japanese 21.2 KB
2024-04-16 08:01
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-04-08 03:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-03-22 07:00
Registration Form
有価証券届出書(新規公開時)
Japanese 3.5 MB

Automate Your Workflow. Get a real-time feed of all Kohjin Bio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kohjin Bio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kohjin Bio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.